abstract |
Provided is a pharmaceutical composition for preventing and treating chronic graft-versus-host disease (cGVHD) containing an anti-CD137 monoclonal antibody. n The pharmaceutical composition containing the anti-CD137 monoclonal antibody as an active component reduces a cytokine produced from a CD4+ T cell, and increases a death of a donor CD4+ T cell, thereby effectively preventing and treating cGVHD, and thus can be useful for allogeneic stem cell transplantation. |